BIOMAT Database Logo BIOMAT Database Logo

Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral oestrogens. 1992

M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
King's College Hospital, Denmark Hill, London, UK.

OBJECTIVE To determine the effect on the bone density of the skeleton after changing from oral oestrogen to subcutaneous oestradiol and testosterone replacement. METHODS Prospective non-randomized single centre study. METHODS Twenty women who were receiving long-term oral oestrogen replacement. Ten changed to oestradiol and testosterone implants; the remaining ten continued with oral oestrogens. METHODS Bone density was measured using dual photon absorptiometry at the lumbar spine and neck of femur at the start of the study and after one year. RESULTS The bone density increased significantly by 5.7% at the spine and by 5.2% at the neck of femur in those women who changed to implant therapy but remained unchanged in those women who continued with oral therapy. CONCLUSIONS Subcutaneous oestradiol and testosterone implants will result in an increase in bone mass even after many years of oral oestrogen replacement therapy.

UI MeSH Term Description Entries
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004343 Drug Implants Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug. Drug Implant,Drug Pellet,Pellets, Drug,Drug Pellets,Implant, Drug,Implants, Drug,Pellet, Drug
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations

Related Publications

M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
Increase in bone mass of older postmenopausal women with low mineral bone density after one year of percutaneous oestradiol implants.
March 1995, British journal of obstetrics and gynaecology,
M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
Endometrial and menstrual response to subcutaneous oestradiol and testosterone implants and continuous oral progestogen therapy in post-menopausal women.
November 1985, Maturitas,
M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
Effects of percutaneous oestradiol versus oral oestrogens on bone density.
December 1994, Maturitas,
M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
Trough oestradiol levels associated with cognitive impairment in post-menopausal women after 10 years of oestradiol implants.
April 2002, Psychopharmacology,
M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
Improvement of the lipid profile in post menopausal women who use estradiol and testosterone implants.
October 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
Long-term oestrogens for the prevention of post-menopausal osteoporosis.
January 1976, Postgraduate medical journal,
M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
Bone mass density in post-menopausal women.
September 1997, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
Oestrogens, gonadotrophins and SHBG during oral and cutaneous administration of oestradiol-17 beta to menopausal women.
December 1982, Acta endocrinologica,
M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
Lower Central Fat Increase Risk of One-Year Muscle Mass Loss in Menopausal Women.
January 2020, Mediators of inflammation,
M Savvas, and J W Studd, and S Norman, and A T Leather, and T J Garnett, and I Fogelman
Endometrial response in post-menopausal women during treatment with percutaneous 17 beta-oestradiol opposed by oral progesterone.
October 1986, Maturitas,
Copied contents to your clipboard!